Mounjaro NHS Expansion June 2026: BMI 35 and the Four Conditions Explained

From 23 June 2026 NHS Mounjaro eligibility expands to BMI 35 with four of five weight-related conditions.

NHS England has confirmed the next phase of its tirzepatide (Mounjaro) rollout for obesity management. Cohort 2 goes live on 23 June 2026. The headline change is that the body mass index threshold drops from 40 to 35. The requirement to have at least four of five specific weight-related health conditions remains in place. On day one, around 100,000 more UK adults will become eligible for this treatment on the NHS. For many people considering their options, the details of which BMI applies, which conditions count, how the prescription actually happens and what the private costs look like in 2026 are not fully clear. This article explains the cohort 2 eligibility criteria, the four qualifying conditions, the practical NHS pathway, the private alternative and what to discuss with your GP.

What is changing on 23 June 2026

The NHS is rolling out tirzepatide for obesity in a phased programme based on NICE technology appraisal TA1026, published in 2024. The first phase, Cohort 1, has been running since June 2025 for adults with a BMI of 40 or above (or 37.5 or above with ethnic adjustment) plus at least four of five weight-related conditions. The new phase, Cohort 2, begins on 23 June 2026. It lowers the BMI requirement to between 35 and 39.9. For those from South Asian, Chinese, Middle Eastern, Black African or African Caribbean backgrounds, the adjusted range is 32.5 to 37.4. The requirement for at least four of the five specified conditions stays the same.

This change makes an estimated 100,000 additional adults in England eligible straight away. The plan is structured over a 12-year horizon. Cohort 3, scheduled for 1 April 2027, will further widen access for the BMI 40 group by reducing the conditions requirement from four out of five to three out of five. The entire programme aims to reach about 220,000 patients in its first three years. In 2026, prescribing is done either through your GP practice if it is participating in the NHS Weight Management Service, or via a referral to that service. Not every GP practice is part of the initial rollout; your local Integrated Care Board decides which are involved. If you do not meet the NHS criteria, you can still access Mounjaro privately, typically costing between 150 and 280 pounds per month.

The five weight-related conditions and the four-of-five rule

To qualify for NHS Mounjaro in Cohort 2, you must have a formal diagnosis of at least four of the following five conditions. These are not self-diagnosed; they must be recorded in your GP medical record.

The five conditions are:

1. Type 2 diabetes.
2. Hypertension (high blood pressure).
3. Dyslipidaemia (this means an unhealthy cholesterol or lipid profile).
4. Established cardiovascular disease. This includes a history of heart attack, stroke, transient ischaemic attack (TIA), peripheral arterial disease, or heart failure.
5. Obstructive sleep apnoea. This must be formally diagnosed, usually following a sleep study, and you may be using a CPAP machine or be under a sleep service.

The threshold of four out of five is deliberately high. It is designed to treat those with the most complex metabolic health needs first, where the absolute health benefit is likely to be greatest. It is worth checking your GP record, as some conditions like hypertension or dyslipidaemia can be under-recorded if you are on medication for them. Ensure your GP has coded the actual diagnosis, not just the prescription. If you currently have three conditions, you will not qualify in Cohort 2. Your options then are to work with your GP to ensure your record is accurate, wait for Cohort 3 in April 2027 which lowers the bar for the BMI 40 group, or explore the private route.

Ethnic BMI adjustment and why it matters

The eligibility criteria include an important ethnic adjustment. For adults from South Asian, Chinese, Middle Eastern, Black African or African Caribbean backgrounds, the BMI thresholds are 2.5 points lower. This is because people from these backgrounds tend to develop weight-related health problems like diabetes and heart disease at a lower BMI than the white European population. The adjustment is a formal part of the NICE guidance.

In practical terms for Cohort 2, a white British adult needs a BMI of 35 to 39.9. An adult from one of the specified ethnic backgrounds needs a BMI of 32.5 to 37.4, plus the same four of five conditions. This adjustment applies at your first eligibility check with your GP. It is important that your GP record accurately reflects your ethnicity, as many records may default to ‘White British’ unless corrected. You should check this and ask for it to be updated before your discussion about Mounjaro. If your GP is unsure about the adjustment, they can refer to the NICE TA1026 commissioning guidance or the local policy from your Integrated Care Board. This adjustment is not optional; it is a core part of the fair access criteria.

The practical NHS pathway in 2026

The journey to getting an NHS Mounjaro prescription follows a series of steps.

First, check your own basics. Know your BMI from a recent height and weight measurement at your GP surgery. Review your list of diagnosed health conditions and ensure they are clearly coded in your record.

Second, book a GP appointment specifically to discuss Mounjaro eligibility. A standard 10 to 20 minute appointment is usually enough. Take a list of your conditions and medications.

Third, your GP will check you against the Cohort 2 criteria: your BMI band, any ethnic adjustment, and confirm you have at least four of the five qualifying conditions formally diagnosed.

Fourth, if you are eligible, you will need blood tests before starting. These typically include HbA1c (for diabetes), a lipid profile (cholesterol), kidney function (urea and electrolytes), and liver function tests.

Fifth, the prescription pathway varies by location. In some areas, your GP can start the prescription directly. In others, you will be referred to the local NHS Weight Management Service for an assessment first, which can involve a wait of several weeks.

Sixth, the medication starts at a 2.5 mg weekly injection. The dose is gradually increased every four weeks as tolerated, up to a maximum of 15 mg. Most people find an effective dose between 7.5 mg and 15 mg.

Seventh, lifestyle support is a mandatory part of the NHS pathway. This includes guidance on diet, physical activity, sleep and mental health.

Eighth, you will have a follow-up review after four to eight weeks to check on side effects and adjust the dose. Continued treatment is reviewed every 6 to 12 months.

Private route in 2026 and the Eli Lilly price increase

If you do not meet the NHS criteria, or prefer not to wait, the private route remains an option. In September 2025, Eli Lilly increased the UK list price for Mounjaro, with the higher doses seeing the largest rises.

Typical private monthly costs in 2026 are:

– 2.5 mg: around 150 pounds
– 5 mg: around 170 pounds
– 7.5 mg: around 190 pounds
– 10 mg: around 220 pounds
– 12.5 mg: around 250 pounds
– 15 mg: around 280 pounds

Major UK providers include Boots Online Doctor, Superdrug Online Doctor, LloydsPharmacy Online Doctor, Numan, Voy, Juniper, Phlo and Asda Online Doctor. The total cost for a year at an effective dose often falls between 2,000 and 3,200 pounds. This compares to an NHS contract price of approximately 92 pounds for a 28-day supply, or about 1,100 pounds per year. The significant cost difference is a primary driver for seeking NHS eligibility. Supply has been intermittent at times, so it is sensible to confirm stock with a pharmacy before committing.

Side effects, contraindications and what to monitor

Being informed about potential side effects is a key part of starting treatment.

Common side effects are gastrointestinal. Nausea is very common, particularly in the first one to four weeks after increasing a dose. Constipation, diarrhoea and indigestion are also reported. These often settle with time.

Less common but more serious side effects include gallstones, which can occur with any significant weight loss. Pancreatitis is rare but requires urgent medical attention if you experience sudden, severe abdominal pain often radiating to your back. Hypoglycaemia, or low blood sugar, is a risk mainly for people also taking insulin or certain diabetes tablets like sulphonylureas. Your GP will usually adjust these other medications before you start Mounjaro.

Mounjaro is not suitable for everyone. It must not be used in pregnancy or while breastfeeding. It is not licensed for type 1 diabetes. Other reasons to avoid it include severe gastroparesis (slow stomach emptying), a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Practical monitoring involves regular weight checks, blood pressure reviews, and for those with diabetes, HbA1c tests every three to six months. Eating smaller, slower meals and staying hydrated can help manage early side effects. The drug is intended as a long-term treatment; stopping it usually leads to significant weight regain over several months unless very intensive lifestyle changes are maintained.

What weight loss to actually expect

It is important to set realistic expectations. The large clinical trials, like SURMOUNT-1, showed an average weight loss of about 20.9 percent at 72 weeks using the maximum 15 mg dose in people without diabetes.

In real-world UK practice over 2025 and 2026, the results are typically more modest. Factors like tolerating the dose, consistent adherence, and baseline habits all play a role. A typical outcome for someone who reaches an effective dose and maintains it for 12 months is a weight loss of 12 to 18 percent of their starting body weight. About 70 percent of patients lose at least 10 percent, and around 30 percent lose 15 percent or more.

Weight loss often plateaus after 12 to 18 months. This is normal. Maintaining the loss usually requires ongoing treatment. If the medication is stopped, most people regain 50 to 70 percent of the weight they lost within a year, unless they have very intensive ongoing lifestyle support. Thinking of Mounjaro as a long-term management tool, much like a blood pressure tablet, is a more accurate frame than a short-term fix.

Frequently Asked Questions

When does the NHS BMI 35 Mounjaro expansion start?

Cohort 2 of the NHS Mounjaro rollout begins on 23 June 2026. From that date, adults with a BMI of 35 to 39.9, or 32.5 to 37.4 with the ethnic adjustment, who also have at least 4 of the 5 qualifying weight-related conditions, become eligible. Cohort 1, for BMI 40 and above, continues unchanged.

What are the 4 of 5 qualifying conditions for NHS Mounjaro?

The five conditions are: type 2 diabetes, hypertension, dyslipidaemia (high cholesterol), established cardiovascular disease (such as a past heart attack or stroke), and obstructive sleep apnoea (formally diagnosed). You need a diagnosis of at least four of these in your GP record to qualify in Cohort 2.

How does the ethnic BMI adjustment work?

For adults from South Asian, Chinese, Middle Eastern, Black African or African Caribbean backgrounds, the BMI thresholds are 2.5 points lower. So for Cohort 2, a BMI of 32.5 to 37.4 plus 4 of 5 conditions qualifies. You must ensure your GP record has your correct ethnicity recorded.

Who prescribes Mounjaro on the NHS in 2026?

Prescribing is managed either by your GP practice if it is participating in the NHS Weight Management Service, or via a referral to that service. Which model applies depends on your local Integrated Care Board. Not all GP practices are involved yet. Blood tests are required before starting.

How much does Mounjaro cost privately in the UK in 2026?

Private costs typically range from 150 pounds per month for the 2.5 mg dose to 280 pounds per month for the 15 mg dose. Major providers include Boots, Superdrug, LloydsPharmacy, Numan and Voy. A full year at an effective dose can cost between 2,000 and 3,200 pounds.

How much weight will I actually lose on Mounjaro?

In trials, average loss was about 20.9 percent at maximum dose. In UK real-world practice, a typical result after 12 months of good adherence is 12 to 18 percent of body weight. Most people lose at least 10 percent. Significant regain is likely if the drug is stopped.

What are the main side effects of Mounjaro?

Common ones are nausea, constipation and diarrhoea, especially after dose increases. Serious side effects like pancreatitis are rare. It cannot be used in pregnancy, with type 1 diabetes, or with a history of certain thyroid cancers. Side effects often improve within a few weeks at a stable dose.

What if I do not meet the 4 of 5 conditions criteria?

You have three main options. First, check with your GP that all your diagnosed conditions are accurately recorded. Second, wait for Cohort 3 from 1 April 2027, which lowers the requirement to 3 of 5 conditions for those with a BMI over 40. Third, consider the private route, which costs 150 to 280 pounds per month.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.